Gene · 81607
Papers1,879
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 1,879
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Enfortumab vedotin demonstrates consistent efficacy in platinum- and ICI-refractory metastatic urothelial carcinoma patients irrespective of prior response: a multicenter real-world study. | Cent European J Urol | 2026 | 42375731 | PubTator, text mining | PubMed |
| Topographical and stage-related expression of nectin-4 in prostate cancer. | Cent European J Urol | 2026 | 42375720 | PubTator, text mining | PubMed |
| Targeting the fusion machinery of Peste des petits ruminants virus: design and in vitro characterization of an HRC-derived antiviral peptide. | Biomed Pharmacother | 2026 | 42372353 | PubTator, text mining | PubMed |
| Human epidermal growth factor receptor-2, nectin-4, and trophoblast cell surface antigen-2 expression varies significantly across ovarian cancer histotypes. | Taiwan J Obstet Gynecol | 2026 | 42362263 | PubTator, text mining | PubMed |
| A Comprehensive Bioinformatic Analysis of SLC52A3 as a Prognostic Biomarker and Potential Therapeutic Target in Gynecological Cancers. | Genes (Basel) | 2026 | 42353828 | PubTator, text mining | PubMed |
| Nectin-4 expression in clear cell renal cell carcinoma. | Sci Rep | 2026 | 42350512 | PubTator, text mining | PubMed |
Comprehensive analysis of antibody-drug conjugate (ADC) targets in adenoid cystic carcinoma: examining antigen expression in relation to clinicopathological features, prognosis, and initial therapeutic outcomes. | Transl Oncol | 2026 | 42341371 | PubTator, text mining | PubMed |
| Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody-drug conjugates. | Cancer Treat Rev | 2026 | 42341369 | PubTator, text mining | PubMed |
| Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC). | ESMO Open | 2026 | 42330841 | PubTator, text mining | PubMed |
| Refractory Diabetic Ketoacidosis Associated with Enfortumab Vedotin: A Pharmacokinetic-Based Management Approach. | Kidney360 | 2026 | 42295856 | PubTator, text mining | PubMed |
| Preclinical Theranostic Study of 68Ga/177Lu/225Ac-Labeled Bicyclic Peptides Targeting Nectin‑4 in Lung Cancer. | ACS Omega | 2026 | 42294171 | PubTator, text mining | PubMed |
| Clinicopathological and molecular characterization of HPV-associated cervical poorly cohesive carcinoma: a rare aggressive entity. | J Pathol Clin Res | 2026 | 42289532 | PubTator, text mining | PubMed |
| FGFR3 Alterations and Nectin-4 Expression as Therapeutic Biomarkers in Bladder Cancer: A Systematic Review and Single-Arm Meta-Analysis. | Int J Mol Sci | 2026 | 42278538 | PubTator, text mining | PubMed |
| Integrated Molecular and Clinical Analysis of Thymic Epithelial Tumors. | JCO Precis Oncol | 2026 | 42258781 | PubTator, text mining | PubMed |
| [ 68 Ga]Ga-NECT-224 PET/CT Shows Increasing Nectin-4 Expression in Progressive Urothelial Carcinoma Under ADC-Therapy With Enfortumab-Vedotin. | Clin Nucl Med | 2026 | 42257446 | PubTator, text mining | PubMed |
| Comprehensive Genomic Characterization Between Urothelial Carcinoma Subtypes/Divergent Differentiation (S/DD) and Pure Urothelial Carcinoma Using a Large-Scale Japanese Genomic Panel Dataset. | Int J Urol | 2026 | 42252959 | PubTator, text mining | PubMed |
| Giant Cell Urothelial Carcinoma: Morphometric Insights and Associations With Aggressive Clinical Features. | Am J Surg Pathol | 2026 | 42252958 | PubTator, text mining | PubMed |
| Nectin-4 drives aggressive tumor biology and poor prognosis in renal cell carcinoma. | Urol Oncol | 2026 | 42247880 | PubTator, text mining | PubMed |
| TRIM71 suppresses cervical cancer progression by inhibiting Nectin4-mediated Wnt/β-catenin signaling. | Biol Direct | 2026 | 42237330 | PubTator, text mining | PubMed |
| B7-H3 (CD276) as a candidate therapeutic target in medullary thyroid cancer. | Endocr Relat Cancer | 2026 | 42227355 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/81607/papers?page=4